Feb 22,2023

mylife Loop offers new remote monitoring feature for parents

Parents and caregivers of children with diabetes can now follow their child's glucose and insulin data via the mylife CamAPS FX app on their own personal smartphone. The new "Companion remote monitoring" feature is fully integrated into the app. It gives parents and caregivers better control and peace of mind. Especially at night, remote diabetes monitoring allows a relaxed sleep and can relieve caregivers considerably. Besides the common display of Continuous Glucose Monitoring (CGM) data, also insulin delivery data, Boost & Ease-Off usage, pump information and other relevant mylife CamAPS FX information can simply be shared with parents and caregivers. mylife YpsoPump and mylife CamAPS FX is the only automated insulin delivery (AID) system that can be connected either to the Dexcom G6 sensor from Dexcom or to the FreeStyle Libre 3 sensor from Abbott. Abbott's FreeStyle Libre 3 sensor has been compatible with mylife Loop in Germany since December 2022. This compatibility will be rolled out in Switzerland, UK and the Netherlands in the first half of 2023.

PRODUCT

#mobile app

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 22,2023

Dexcom Showcases Accuracy, Simplicity and Connectivity of Its CGM Portfolio at ATTD Conference as Access to CGM Expands Globally

DexCom, Inc. will showcase the strength of its CGM portfolio and unveil new clinical and real-world evidence that continues to demonstrate the effectiveness of Dexcom CGM at the 16th International Conference on Advanced Technologies and Treatments for Diabetes held Feb. 22-25, 2023 in Berlin. Feedback from initial Dexcom G7 users has been positive, with consistent praise for the 60% smaller wearable, short warmup period on the market and more engaging and consumer-friendly mobile app. In addition, 97% of initial users surveyed found Dexcom G7 easy to use. The company also shared in the press release that from Spain to Estonia and the UK, more and more people living with diabetes are gaining access to real-time CGM as Dexcom ONE continues to launch in additional markets.

CONFERENCES

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 22,2023

Tandem Diabetes Care Appoints New Chair of Board of Directors

Tandem Diabetes Care, Inc. today announced the appointment of Rebecca Robertson as Chair of its Board of Directors. Ms. Robertson, who joined Tandem’s Board as an independent director in January 2019, succeeds Kim Blickenstaff, who will continue as a member of the Board.

View Analyst & Ambassador Comments
Go to original news
Feb 22,2023

Tandem Diabetes Care Announces Fourth Quarter 2022 Financial Results and Full Year 2023 Financial Guidance

Tandem Diabetes Care, Inc. today reported its financial results for the quarter and year ended December 31, 2022 and provided its financial guidance for the year ending December 31, 2023. GAAP gross profit in Q4 2022 increased to $115.5 million, compared to $113.7 million in Q4 2021. Full Year 2022 financial results compared to Full Year 2021 showed that GAAP gross profit increased to $413.0 million, compared to $376.2 million. GAAP gross margin was 52 percent, compared to 54 percent.

View Analyst & Ambassador Comments
Go to original news
Feb 22,2023

Delve Health and UW Medicine Announce a Collaboration to Access Remote Data Capture for Diabetes Research

Delve Health and UW Medicine are announcing a collaboration to provide new insights into endemic Type 2 Diabetes research, through artificial intelligence and machine learning (i.e., AI/ML) and remote data capture via Delve Health’s digital healthcare platform. Delve Health’s Clinical StudyPal, a mobile and web-based platform that enables decentralized clinical trial research and remote patient monitoring, has been configured to capture patient data, 24-hours a day, through a wearable device (i.e., smart watch). NIH-funded Bridge2AI project called Artificial Intelligence Ready Equitable Atlas for Diabetes Insight (AI-READI; award project number 1OT2OD032644-01) will collect and release a flagship medical dataset for salutogenesis that will hopefully accelerate machine learning applications and generate novel hypotheses about Type 2 Diabetes Mellitus.

COLLABORATION PARTNERSHIP

#r&d

#rpm

View Analyst & Ambassador Comments
Go to original news
Feb 21,2023

Lilly to Participate in Cowen's 43rd Annual Health Care Conference

Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 43rd Annual Health Care Conference on Monday, March 6, 2023. Mike Mason, executive vice president and president, Lilly Diabetes and Obesity, will participate in a fireside chat at 1:30 p.m., Eastern time.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 21,2023

Dexcom G6 Continuous Glucose Monitoring System Launches in Singapore

Dexcom, Inc. announced today the launch of its Dexcom G6 CGM System in Singapore for people with diabetes ages two years and older, including pregnant women, and the appointment of DKSH Singapore Pte Ltd as sales, marketing, and distribution service provider.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 21,2023

ASCENSIA DIABETES CARE COLLABORATES WITH SNAQ TO SUPPORT MEALTIME DECISION-MAKING FOR PEOPLE WITH DIABETES

Ascensia Diabetes Care announced today that it entered into a global collaboration with diabetes management company Snaq. Snaq develops an app-based solution offering insights on food and nutrition for people with diabetes. Users of the Contour portfolio can integrate Snaq into their diabetes management regimen. Through the Snaq app, users can take a photo of their food and receive nutritional information and actionable insights to facilitate glycemic control. Snaq offers easy-to-read graphs and comparisons to previous meals. The companies entered into an initial three-year collaboration. It reaches across multiple phases and regions, with a U.S. launch representing the first step. In addition to integration with Contour devices, Snaq meal data can also be shared with Ascensia’s GlucoContro.Online platform.

PRODUCT

#mobile app

#bgm

View Analyst & Ambassador Comments
Go to original news
Feb 21,2023

Highly Anticipated Omnipod® 5 Real-World Evidence to be Presented at the 16th International Conference on Advanced Technologies & Treatments for Diabetes(ATTD)

Insulet Corporation today announced the presentation of new real-world evidence related to the Omnipod® 5 Automated Insulin Delivery System at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place February 22 – 25, 2023 in Berlin, Germany, and online. The first release of Omnipod 5 real-world data will be presented at Insulet’s symposium, “Innovating Today for a Better Tomorrow: How Omnipod 5 Automated Insulin Delivery System is Changing Diabetes Care.” The Insulet-sponsored symposium will take place on Wednesday, February 22, from 4:15 to 5:45 p.m. CET. In addition, Insulet will present new Omnipod 5 data on the optimization of insulin to carbohydrate ratio settings during the three-month pivotal studies for children and adults with type 1 diabetes.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 20,2023

Innovation Zed Announces CE Mark of New Technology InsulCheck DOSE: An Add-on Device That Automatically Logs the Time and Dialled Dosage for Insulin Pen Users

Innovation Zed, an Irish R&D company specialising in the design, development and manufacturing of medical technologies, announced today it has secured a CE Mark for the InsulCheck DOSE add-on device. InsulCheck DOSE is a single-unit add-on device for pen injectors that automatically captures dose value dialled, injection event time stamp and temperature as well as mounting and unmounting events. With InsulCheck DOSE, real-time injection event data are logged and sent automatically to a compatible display device.

REGULATORY CE MARK

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES